Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
27
NBY Quote, Financials, Valuation and Earnings
Last price:
$2.09
Seasonality move
:
-9.16%
Day range:
$0.51 - $0.75
52-week range:
$2.17 - $99.75
Dividend yield:
0%
P/E ratio:
5.05x
P/S ratio:
5.84x
P/B ratio:
1.50x
Volume:
1.6M
Avg. volume:
2.4M
1-year change:
-6.57%
Market cap:
$77.9M
Revenue:
$9.8M
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
YCBD
cbdMD, Inc.
|
$4.9M | -- | 11.43% | -- | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.01 | $0.85 | $77.9M | 5.05x | $4.00 | 0% | 5.84x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
SAVA
Cassava Sciences, Inc.
|
$2.13 | $8.00 | $102.9M | -- | $0.00 | 0% | 2.69x |
|
SVRA
Savara, Inc.
|
$5.53 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
YCBD
cbdMD, Inc.
|
$0.95 | $2.00 | $8.5M | -- | $0.00 | 0% | 0.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -2.840 | 8.08% | 1.85x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.633 | -- | 2.21x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
|
YCBD
cbdMD, Inc.
|
6.18% | 1.102 | 4.93% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
YCBD
cbdMD, Inc.
|
$2.8M | -$286.3K | -39.12% | -47.18% | -5.71% | -$977.3K |
NovaBay Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns NBY or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of 25.76%. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About NBY or ACAD?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -71.72%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is NBY or ACAD More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.135, which suggesting that the stock is 86.499% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock NBY or ACAD?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $4.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or ACAD?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.05x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 5.84x versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.5.84x 5.05x $521K -$1.3M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns NBY or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of 16.99%. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About NBY or ALNY?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -71.72%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is NBY or ALNY More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.135, which suggesting that the stock is 86.499% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock NBY or ALNY?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $4.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or ALNY?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.05x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 5.84x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.5.84x 5.05x $521K -$1.3M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns NBY or SAVA?
Cassava Sciences, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Cassava Sciences, Inc.'s return on equity of -86.98%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M SAVACassava Sciences, Inc.-- -$0.22 $81.6M -
What do Analysts Say About NBY or SAVA?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -71.72%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 275.59%. Given that Cassava Sciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cassava Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 SAVACassava Sciences, Inc.1 0 0 -
Is NBY or SAVA More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.135, which suggesting that the stock is 86.499% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -0.628, suggesting its less volatile than the S&P 500 by 162.76%.
-
Which is a Better Dividend Stock NBY or SAVA?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $4.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or SAVA?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Cassava Sciences, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.05x while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 5.84x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.5.84x 5.05x $521K -$1.3M SAVACassava Sciences, Inc.2.69x -- -- -$10.8M
-
Which has Higher Returns NBY or SVRA?
Savara, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About NBY or SVRA?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -71.72%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that Savara, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Savara, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 SVRASavara, Inc.6 0 0 -
Is NBY or SVRA More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.135, which suggesting that the stock is 86.499% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock NBY or SVRA?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $4.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or SVRA?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Savara, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Savara, Inc.'s net income of -$29.6M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.05x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 5.84x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.5.84x 5.05x $521K -$1.3M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns NBY or YCBD?
cbdMD, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of -5.64%. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat cbdMD, Inc.'s return on equity of -47.18%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M YCBDcbdMD, Inc.54.93% -$0.04 $9.6M -
What do Analysts Say About NBY or YCBD?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -71.72%. On the other hand cbdMD, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 110.55%. Given that cbdMD, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe cbdMD, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 YCBDcbdMD, Inc.0 0 0 -
Is NBY or YCBD More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.135, which suggesting that the stock is 86.499% less volatile than S&P 500. In comparison cbdMD, Inc. has a beta of 2.140, suggesting its more volatile than the S&P 500 by 114.035%.
-
Which is a Better Dividend Stock NBY or YCBD?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $4.00 per share corresponding to a yield of 0%. cbdMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. cbdMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or YCBD?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are smaller than cbdMD, Inc. quarterly revenues of $5M. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is lower than cbdMD, Inc.'s net income of -$283.1K. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.05x while cbdMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 5.84x versus 0.30x for cbdMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.5.84x 5.05x $521K -$1.3M YCBDcbdMD, Inc.0.30x -- $5M -$283.1K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 23
RingCentral, Inc. [RNG] is down 12.48% over the past day.
Sell
9
FROG alert for Feb 23
JFrog Ltd. [FROG] is down 7.95% over the past day.
Buy
72
SNSE alert for Feb 23
Sensei Biotherapeutics, Inc. [SNSE] is down 2.63% over the past day.
